Myopia occupies a strange place in medicine. We measure it in the clinic, screen children for it, and write prescriptions for it. Yet it is still often treated less like a clinical disease than a refractive inconvenience, solved with a new pair of glasses.
I am myopic. My day begins with reaching for my glasses before I can safely reach for much else. I have tried soft daily contacts, glasses that fog under masks and slide down my nose, and hard corrective lenses that make each blink feel like my eye is negotiating with a foreign object. None of this makes me unique. Millions of people live with myopia. But that familiarity may be part of the problem. Because myopia is so common, we have learned to treat it as ordinary. Because it can often be corrected, we assume it is no longer an issue.
I began to question that thinking when I started volunteering at free clinics, where I help patients access donated glasses. One child I remember sat quietly during a screening, guessing at letters that were supposed to be visible. At first, the hesitation looked like shyness. Eventually, it became clear that the child simply could not see what the rest of us could. A parent had long known their child needed help, but eye exams, glasses, and transportation were costs they could not afford.
Right now, too much pediatric myopia sits in purgatory between medicine and merchandise. Families are told their child needs correction, but the cost and logistics of that correction are often treated as private burdens. The National Academies noted that the cost of prescription glasses can be a barrier to treatment, particularly for children with low socioeconomic status. A systematic review in BMC Public Health found that spectacle correction for children with vision impairment from uncorrected refractive error can improve educational, cognitive, psychological, mental health, and quality-of-life outcomes. If glasses can alter a child’s ability to learn and function, access to them is not a minor convenience. It is healthcare.
For a child, blurry distance vision can mean not seeing the board, avoiding sports, developing headaches, falling behind, or learning to stop asking for help. For a parent, it can mean being told the problem is simple while facing a system that makes the solution difficult to obtain. And for clinicians, it should raise a deeper question: If a child’s eye is changing over time in a way that increases future risk, why do we keep describing the condition as though it were only consumer correction?
In 2024, the National Academies of Sciences, Engineering, and Medicine directly challenged that framing, recommending that myopia be classified as a disease requiring a medical diagnosis. Progressive childhood myopia is not merely the experience of blurry vision. It often reflects axial elongation of the eye, a structural change that can continue as children grow. A review and meta-analysis in Investigative Ophthalmology & Visual Science found that myopia is associated with increased risk of visual impairment, myopic macular degeneration, retinal detachment, cataracts, and open-angle glaucoma. The risk is highest in high myopia, but it does not exist only at the extremes. Progressive myopia is tied to future ocular morbidity in ways that our current language often obscures.
Medicine usually understands progression. We would not describe pediatric asthma as a child “just needing an inhaler” and stop there. We would ask whether symptoms are worsening, what triggers are contributing, and whether the family has access to treatment that can prevent long-term harm. Progressive myopia deserves the same kind of clinical seriousness.
The effects of myopia are not only anatomical. A nationwide adolescent study in Eye found that myopia was associated with a higher prevalence of anxiety and mood disorders, with greater psychosocial burden as severity increased. That finding makes intuitive sense to anyone who has depended on lenses to navigate the world. Vision shapes confidence, independence, school participation, sports, and social life. A child who cannot see clearly is missing pieces of childhood that everyone else assumes are visible.
Classifying myopia as a disease would allow for prevention and progression control. If myopia is treated only as blurred vision, sharper vision becomes the endpoint. If it is treated as a progressive pediatric condition, slowing that progression becomes part of care. The National Academies found strong evidence that increased outdoor time reduces the risk of developing myopia by slowing excessive eye growth. For selected children, clinicians may also consider interventions such as low-dose atropine, which reduced progression in the LAMP study, or FDA-approved MiSight 1 Day contact lenses, which are indicated for slowing myopia progression in children who meet treatment criteria.
I still think about how quickly my own day narrows when I cannot find my glasses. That experience is temporary because I have access to what I need. But for many children, blur is not a brief inconvenience at the beginning of the morning. It is a lived experience that follows them into the classroom, onto the playground, and through every part of daily life.
Calling myopia a disease will not solve every barrier. It will not create appointments where none exist or pay for every lens overnight. But disease classification would change what our system is prepared to do. The National Academies has argued that classifying myopia as a disease would help move the field beyond treating blur alone and toward coordinated prevention, management, surveillance, and accountability. A recent review on access to myopia care in the U.S. similarly frames care as a continuum of detection, treatment, and long-term management, rather than a one-time purchase of corrective lenses. Correctly naming myopia influences what we cover, what we research, what we track, and what we decide is worth preventing. Myopia is more than a refractive error, so let’s call it what it is.
How do you think calling myopia a disease will help treatment? Share in the comments.
